Clinical Trial Update: CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for CUDC-907 in metastatic and locally advanced thyroid cancer; study terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Poorly Differentiated Thyroid Cancer
• Thyroid Neoplasms
• Undifferentiated Thyroid Cancer

Drugs mentioned

• CUDC-907 (fimepinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-12-21